Publications by authors named "F Coenjaerts"
Article Synopsis
- HPIV-3 causes serious respiratory infections, and current small-animal models for studying it are inadequate, but AG129 mice effectively replicate the virus's effects.
- Research showed that HPIV-3 targets specific lung cells and leads to significant lung damage, but does not spread between cohabitating infected and non-infected mice.
- Treatment with GS-441524, a remdesivir component, decreased the virus in the lungs and improved lung health, suggesting AG129 mice are useful for testing new treatments and preventative measures for HPIV-3 in humans.
Importance: Staphylococcus aureus surgical site infections (SSIs) and bloodstream infections (BSIs) are important complications of surgical procedures for which prevention remains suboptimal. Contemporary data on the incidence of and etiologic factors for these infections are needed to support the development of improved preventive strategies.
Objectives: To assess the occurrence of postoperative S aureus SSIs and BSIs and quantify its association with patient-related and contextual factors.
Article Synopsis
- Ventilator-associated pneumonia from Pseudomonas aeruginosa in hospitalized patients leads to high mortality, prompting the testing of the bispecific monoclonal antibody MEDI3902 (gremubamab) to prevent this condition in patients who are colonized with the bacteria.
- The EVADE study (NCT02696902) was a double-blind, placebo-controlled trial that recruited mechanically ventilated adults colonized with Pseudomonas aeruginosa and randomized them to receive either MEDI3902 or a placebo, focusing on the incidence of pneumonia over 21 days post-treatment.
- Results showed no significant difference in the incidence of pneumonia between the MEDI3902 and placebo groups, with 22.4
Efficacy and safety of suvratoxumab for prevention of Staphylococcus aureus ventilator-associated pneumonia (SAATELLITE): a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial.
Lancet Infect Dis
September 2021
Background: Staphylococcus aureus remains a common cause of ventilator-associated pneumonia, with little change in incidence over the past 15 years. We aimed to evaluate the efficacy of suvratoxumab, a monoclonal antibody targeting the α toxin, in reducing the incidence of S aureus pneumonia in patients in the intensive care unit (ICU) who are on mechanical ventilation.
Methods: We did a multicentre, randomised, double-blind, placebo-controlled, parallel-group, phase 2 pilot trial at 31 hospitals in Belgium, the Czech Republic, France, Germany, Greece, Hungary, Portugal, Spain, and Switzerland.
Article Synopsis
- - The study aimed to explore the differences in clinical impact among various rhinovirus (RV) species in adults suffering from acute cough or lower respiratory tract infections (LRTI), compared to asymptomatic individuals.
- - Conducted across 16 primary care networks in 11 European countries between 2007 and 2010, the research involved analyzing RV detection through advanced molecular methods, revealing that RV-A was the most common species linked to higher risks of LRTI.
- - Results showed RV-A led to more severe symptoms compared to RV-B and RV-C, with a higher viral load in symptomatic cases; intriguingly, RV-B infections appeared more often in asymptomatic individuals.